UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB

      X    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

               For the quarterly period ended September 30, 2004

      _    TRANSITION  REPORT  UNDER  SECTION  13 OR  15(d)  OF THE  SECURITIES
           EXCHANGE ACT OF 1934
                     For the transition period from           to
                        Commission File Number 000-24541

                         CORGENIX MEDICAL CORPORATION
                (Name of Small Business Issuer in its Charter)


              Nevada                           93-1223466
  (State or other jurisdiction of    (I.R.S. Employer Identification
  incorporation or organization)                  No.)


                12061 Tejon Street, Westminster, Colorado 80234

         (Address of principal executive offices, including zip code)

                                 (303) 457-4345

                (Issuer's telephone number, including area code) Former name,
former address and former fiscal year, if changed since
      last report)

Check  whether  the  issuer:  (1) filed  all  reports  required  to be filed by
Section  13 or 15(d) of the  Exchange  Act  during  the past 12 months  (or for
such shorter  period that the  registrant  was required to file such  reports),
and  (2)  has  been  subject  to  such  filing  requirements  for  the  past 90
days.     Yes X   No  ___

The number of shares of Common Stock outstanding was 5,324,818 as of November
12, 2004.

Transitional Small Business Disclosure Format.     Yes _   No X
<page>


                          CORGENIX MEDICAL CORPORATION


                               September 30, 2004





                                TABLE OF CONTENTS


                                                                        Page


                                     Part I


                              Financial Information


      Item 1.   Consolidated Financial Statements                       3


      Item 2.   Management's Discussion and Analysis or Plan of
                Operation

      Item 3.   Controls and Procedures                                15




                                     Part II


                                Other Information


      Item 1.   Legal Proceedings                                      21


      Item 2.   Changes in Securities and Use of Proceeds              21


      Item 3.   Defaults Upon Senior Securities                        21


      Item 4.   Submission of Matters to a Vote of Security Holders    21


      Item 5.   Other Information                                      21


      Item 6.   Exhibits and Reports on Form 8-K                       21


      Certifications                                                   24



<page>

                                     PART I
                   Item 1. Consolidated Financial Statements
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
Consolidated Balance Sheets
-------------------------------------------------------------------------------


                                     September 30,2004          June 30, 2004
                                       (Unaudited)
                Assets
Current assets:
  Cash and cash equivalents             $426,954                  468,954
  Accounts receivable, less allowance
    for doubtful accounts of  $30,410
    and $13,410                          728,280                  834,153
  Inventories                          1,110,339                  982,227
  Prepaid expenses                        44,202                   30,276
          Total current assets         2,309,775                2,315,610

Equipment:

 Capitalized software costs              122,855                  122,855
  Machinery and laboratory equipment     633,619                  588,219
  Furniture, fixtures, leaseholds
  & office equipment                     517,879                  511,488
                                        ----------              ----------
                                       1,274,353                1,222,562
 Accumulated depreciation and
       amortization                     (940,370)                (913,020)
                  Net equipment          333,983                  309,542

Intangible assets:
  Patents, net of accumulated
       amortization of  $1,038,098
       and $1,019,474                    79,446                   98,070
  Goodwill                               13,677                   13,677
               Net intangible assets     93,123                  111,747
  Due from officer                       12,000                   12,000
  Other assets                           97,144                   98,925
               Total assets          $2,846,025                2,847,824
                                     ==========                ==========
                 Liabilities and Stockholders' Equity (Deficit)
Current Liabilities:
  Current portion of  notes payable,
      net of discount             $    653,454                   569,988
  Current portion of capital
lease obligations                       48,435                    51,395
  Accounts payable                     634,282                   483,642
  Accrued payroll and
      related liabilities              169,370                   173,392
  Accrued interest                     136,600                   127,831
  Accrued liabilities                  125,976                   169,929
                                      --------                  ---------
       Total current liabilities     1,768,117                 1,576,177

Notes payable, excluding
      current portion                  203,269                   238,445
Capital lease obligations,
      excluding current portion         37,298                     9,712

        Total liabilities            2,008,684                 1,824,334

Redeemable common stock, 880,282 shares issued and outstanding, aggregate
   redemption value of $500,000, net of unaccreted discount and issuance costs
   of $43,280 and $64,919 at September 30, 2004 and
   June 30, 2004, respectively          456,720                  435,081
Stockholders' equity (deficit):
Preferred stock, $0.001 par value.
Authorized 5,000,000 shares, none
  issued or outstanding Common stock,
  $0.001 par value.  Authorized 40,000,000
 shares; issued  and outstanding and
  5,324,818 and 5,321,319 on September
  30 and June 30,  respectively          4,444                      4,440
Additional paid-in capital           5,452,736                  5,449,100
Accumulated deficit                 (5,065,605)                (4,856,767)
Accumulated other comprehensive
  income                               (10,954)                   (11,364)

      Total stockholders' equity       380,621                     588,409
Total liabilities and stockholders'
    equity                           $2,846,025                   2,847,824
See accompanying notes to consolidated financial statements.
<page>


                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES

Consolidated Statements of Operations

-------------------------------------------------------------------------------

                                       Three Months Ended

                                       September 30, September 30,
                                            2004          2003
                                       ---------------------------
                                        (Unaudited) (Unaudited)
-------------------------------------------------------------------------------

Net sales                           $    1,303,071        1,202,330
Cost of sales                              557,222          471,676
                                        ----------        -----------
   Gross profit                     $      745,849          730,654


Operating expenses:
  Selling and marketing                    375,938          313,712

  Research and development                 156,558         187,887

  General and administrative               299,349         269,560
                                       -----------------------------

  Total expenses                           831,845         771,159


          Operating  loss            $     (85,996)        (40,505)


Interest expense, net                      104,203          24,875
                                       -----------------------------

Net loss                             $    (190,199)        (65,380)
Accretion of discount on redeemable
  common stock                              21,639          21,639
                                       -----------------------------

Net loss available to common
stockholders                             (211,838)         (87,019)

 Net loss per common share, basic and
diluted                              $      (0.04)           (0.02)


Weighted average shares outstanding,
   basic and diluted                     5,324,818       5,294,477

          Net loss                   $    (190,199)       (65,380)

 Other comprehensive loss-foreign
 currency translation income (loss)            410          (437)
                                       ------------------------------

 Total comprehensive loss            $    (189,789)      (65,817)

See accompanying notes to consolidated financial statements.



<page>
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
                 Consolidated Statement of Stockholders' Equity
                  For the three months ended September 30, 2004
                                   (Unaudited)

                Common                                  Accumulated
                Stock,    Common  Additional              other        Total
                Number    Stock,  paid-in   Accumulated    comp.    stckhlders'
              of Shares   Amount  capital     Deficit     income       equity

Balance at
June 30, 2004  5,321,31  $ 4,440  5,449,100 (4,853,767)   (11,364)    588,409

Issuance of common
stock and stock
options for
services          3,499       4      3,636                              3,640
Foreign currency
translation                                                   410         410
Accretion of discount
on redeemable
common stock                                  (21,639)                 (21,639)
Net loss                                     (190,199)                (190,199)
                       ---------------------------------------------------------
                       ---------------------------------------------------------

Balance at
September 30,
2004             5,324,81 $4,444  5,452,736  (5,065,605)    (10,954)    380,621
See accompanying notes to consolidated financial statements.


<page>
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES



Consolidated Statements of Cash Flows
-------------------------------------------------------------------------------

                                                        Three Months
                                                          Ended
                                               September 30,  September 30,
                                                  2004            2003
                                               ----------------------------
                                                (Unaudited) (Unaudited)
Cash flows from operating activities:
  Net loss                                        (190,199)      (65,380)
  Adjustments to reconcile net income to
 net cash used in operating activities:
             Depreciation and amortization          46,068        49,549

            Accretion of discount on
              note payable                          83,903           -
             Equity instruments issued
              for services                           3,639          5,121
             Changes in operating assets and liabilities:
                  Accounts receivable, net         105,093        (99,397)
                  Inventories                     (128,186)       (74,084)
                  Prepaid expenses, due
                  from officer and other assets    (12,250)        (5,356)
                 Accounts payable                  151,885         66,259
                 Accrued payroll and
                 related liabilities                (2,343)       (14,865)
                 Accrued liabilities,
                 including accrued interest        (36,752)       (18,424)
                                               ------------------------------

                 Net cash provided
                 (used) in operating
                 activities                         20,858      (156,577)
                                               ------------------------------

Cash flows used by investing activities:
   Additions to equipment                           (6,528)        (3,695)
                                               ------------------------------

Cash flows from financing activities:
  Proceeds from issuance of notes payable             -            90,936
Payments on notes payable                        (35,614)       (43,418)
Payments on capital lease obligations            (20,774)       (22,530)
                                               ------------------------------
                 Net cash provided
                (used) by financing activities (56,388) 24,988
                                                 ------------------------------

                Net decrease  in cash and
                cash equivalents                   (42,058)      (135,284)

Impact of foreign currency translation
adjustment on cash                                      58           (437)

Cash and cash equivalents at beginning of
period                                             468,954        342,377
                                               -------------------------------

Cash and cash equivalents at end of period     $   426,954        206,656
                                               -------------------------------

Supplemental cash flow disclosures:
  Cash paid for interest                       $    11,443         12,541
Equipment acquired under capital leases        $    45,400             -
See accompanying notes to consolidated
financial statements.



<page>
                 CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES

                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 Corgenix Medical Corporation ("Corgenix" or the "Company") is engaged in the
research, development, manufacture, and marketing of in vitro (outside the body)
diagnostic products for use in disease detection and prevention. We currently
sell 73 diagnostic products on a worldwide basis to hospitals, clinical
laboratories, commercial reference laboratories, and researchinstitutions. Our
corporate headquarters is located in Westminster, Colorado. We have two wholly
owned operating subsidiaries:

o     Corgenix, Inc., ("Corgenix, Inc.") (formerly REAADS), established in
           1990 and located in Westminster, Colorado. Corgenix, Inc. is
           responsible for sales and marketing activities for North America,
           and also conducts product development, product support, regulatory
           affairs and product manufacturing of the Diagnostic Products.

o          Corgenix (UK) Ltd., ("Corgenix UK"), incorporated in the United
           Kingdom in 1996 (formerly REAADS Bio-Medical Products (UK) Limited),
           is located in Peterborough, England. Corgenix UK manages the
           Diagnostic Products Business' international sales and marketing
           activities except for distribution in North America, which is under
           the responsibility of Corgenix, Inc.

On October 15, 2004 the Company and Genesis Bioventures, Inc. (which we refer to
as GBI or Genesis) a biomedical development company focused on the development
of diagnostic tests signed an amendment to the May 21, 2004 Amended and Restated
Agreement and Plan of Merger , extending the closing date for the proposed
merger to on or before February 28, 2005.

If the merger were consummated, then Genesis would issue 14 million shares in
exchange for 100% of Corgenix's outstanding shares. In addition, Genesis would
issue an additional 7 million shares to Corgenix shareholders of record on the
date the merger is consummated if Genesis shares do not trade at a price of at
least $.53 per share for 12 trading days in any consecutive twenty trading day
period during the period from October 15, 2004 to nine months immediately
following the consummation of the merger. The consummation of the merger is
conditioned upon specific closing conditions, including approval by the
shareholders of each company and upon the successful completion of a second
round of merger-related financing (the "Takeout Financing") in the amount of at
least $6,000,000. The terms of the amended agreement further provide for a limit
to the maximum number of Corgenix dissenting shares allowed, and the ability of
Corgenix to terminate the merger, without penalty, at any time prior to November
30, 2004, if in the Company's sole discretion, management is not satisfied with
the terms or the progress of the Takeout Financing, or as a consequence of any
material adverse change in the financial condition of Genesis. As mentioned
below, upon a termination of the merger agreement, the unpaid principal plus
accrued\ interest thereon is payable in four fully amortized semi-annual
payments. The terms of the merger agreement also provide that Corgenix's current
management team will assume the responsibility of managing the combined entity,
which will continue to be known as Genesis Bioventures, Inc. and will be
headquartered in Westminster, Colorado, the location of Corgenix's current
corporate headquarters. The foregoing dates and amounts of these provisions may
be waived upon the mutual consent of both companies. The Takeout Financing would
provide the combined companies with funding to continue to develop and further
expand their respective technologies and sales and marketing activities.
Finally, in the event of a breach of the Merger Agreement, the breaching party
may be liable for up to $1,500,000 of liquidated damage penalties.

On March 24, 2004 Genesis advanced $500,000 to the Company in the form of a
Convertible Promissory Note ("Bridge Note"), for on-going business operations as
well as merger related expenses. Interest will accrue on the principal balance
of the Bridge Note only if the merger is not completed and the merger agreement
is terminated, in which case the interest will accrue at the prime rate at the
time of such termination and from said date of termination. Upon a termination
of the merger agreement, the unpaid principal plus accrued interest thereon is
payable in four fully amortized semi-annual payments. Depending upon the reason
for a termination of the merger agreement, the lender (Genesis) may elect to
convert the unpaid principal balance of the Bridge Note plus accrued but unpaid
interest thereon (if any) into shares of common stock of Corgenix, at a
conversion price of $.40 per share if the termination is due to the unrightful
refusal to close by Corgenix, or at a conversion price of $.568 per share if the
termination is for any other reason. The market value of the Company's stock had
increased from the date of the letter of intent to the date the Bridge Note was
executed, resulting in a beneficial conversion feature which was credited to
equity, and an equal amount is being recognized as interest expense over the
potential term of the Bridge Note.
The accompanying consolidated financial statements have been prepared without
audit and in accordance with accounting principles generally accepted in the
United States for interim financial information and with the instructions to
Form 10-QSB and Article 10 of Regulation S-X. Accordingly, they do not include
all of the information and footnotes required by accounting principles generally
accepted in the United States for complete financial statements. In the opinion
of the Company, the financial statements include all adjustments (consisting of
normal recurring accruals and adjustments) required to present fairly the
Company's financial position at September 30, 2004 and June 30, 2004 and the
results of operations for each of the three month periods ended September 30,
2004 and 2003, and the cash flows for each of the three month periods then
ended. The operating results for the three months ended September 30, 2004 are
not necessarily indicative of the results that may be expected for the year
ended June 30, 2005. For further information, refer to the consolidated
financial statements and footnotes thereto included in the Company's annual
report on Form 10-KSB for the fiscal year ended June 30, 2004.Management of the
Company has made a number of estimates and assumptions relating to the reporting
of assets and liabilities and the disclosure of contingent assets and
liabilities to prepare these financial statements in conformity with accounting
principles generally accepted in the United States of America. Significant
assumptions inherent in the preparation of the accompanying financial statements
include, but are not limited to, revenue recognition and allowances for doubtful
accounts, the provision for excess and obsolete inventories, and commitments and
contingencies. Actual results could differ from those estimates. 2. EARNINGS PER
SHARE Basic earnings (loss) per share is computed by dividing net loss
attributable to common stockholders by the weighted average number of common
shares outstanding. Diluted earnings (loss) per share is computed by dividing
net loss attributable to common stockholders by the weighted average number of
common shares outstanding increased for potentially dilutive common shares
outstanding during the period. The dilutive effect of stock options and their
equivalents is calculated using the treasury stock method. No stock options were
granted in the quarter ended September 30, 2004 or 2003. Options and warrants to
purchase common stock totaling 114,859 and 153,439 shares for fiscal quarters
ended September 30, 2004 and 2003 respectively, are not included in the
calculation of weighted average common shares-diluted below as their effect is
anti-dilutive. Redeemable common stock is included in the common shares
outstanding for purposes of calculating net income (loss) per share.

The components of basic and diluted income (loss) per share are as follows:

                                       3 months ended         3 months ended
                                      September 30, 2004      September 30, 2003
                                      ------------------------------------------
                                                     (unaudited)
Net loss available to common
        stockholders                   $ (211,838)                 (87,019)

Common and common equivalent shares outstanding:
     Historical common shares outstanding
     at beginning of period             5,321,319                5,271,192
     Weighted average common shares
     issued during the period               3,499                   23,285
         Weighted average common shares
            basic and diluted           5,324,818                5,294,477

Net income (loss) per share
    basic and diluted                 $     (0.04)                  (0.02)


3. INCOME TAXESA valuation allowance was provided for deferred tax assets, as
the Company is unable to conclude under relevant accounting standards that it is
more likely than not that deferred tax assets will be realizable.
 4. SEGMENT INFORMATION
The Company has two segments of business: domestic and international operations.
International operations primarily transact sales with customers in Europe and
continents other than North America, while domestic operations transact sales
primarily in North America. The following table sets forth selected financial
data for these segments for the three-month periods ended September 30, 2004 and
2003.


                                        Three Months Ended September 30

                            Domestic            International         Total

Net sales   2004        $   974,275              328,796             1,303,071
            2003        $   930,195              272,135             1,202,330

Net income
/(loss)     2004        $  (258,028)              67,829              (190,199)
            2003        $  (131,570)              66,190               (65,380)

Depreciation
/amortization 2004      $    45,504                 564                 46,068
              2003      $    40,246                 513                 40,759

Interest expense,
net           2004      $   103,189                1,014               104,203
              2003      $    21,595                3,280                24,875

Segment assets
September 30, 2004       $2,526,501              319,524             2,846,025
June 30, 2004            $2,157,074              395,904             2,552,978

5. REDEEMABLE COMMON STOCK

On July 1, 2002, as part of the Medical & Biological Laboratories Co., Ltd.
(MBL) Agreement, MBL purchased shares of the Company's common stock for
$500,000, which MBL can require the Company to repurchase at the same price in
the event that a previously existing distribution agreement with RhiGene, Inc.
is terminated. For no additional consideration, MBL was also issued warrants to
purchase an additional 880,282 shares of Common Stock at a price of $.568 per
share, which is equal to an aggregate amount of $500,000. These warrants expire
on July 3, 2007 and may be exercised in whole or in part at any time prior to
their expiration. The estimated fair value of the warrant upon issuance was
calculated as $401,809 using the Black-Scholes option-pricing model with the
following assumptions: no expected dividend yield, 143% volatility, risk free
interest rate of 4.2% and an expected life of five years. The gross proceeds of
$500,000 were allocated $277,221 to redeemable common stock and $222,779 to the
related warrants based on the relative fair values of the respective instruments
to the fair value of the aggregate transaction. Issuance costs and the discount
attributed to the redeemable common stock upon issuance are being accreted over
the 33-month period prior to the presently expected first date on which the put
option may be exercised, which is the present expiration date of the
distribution agreement between the Company and RhiGene, Inc. Furthermore,
pursuant to the agreement with MBL, as long as MBL holds at least 50% of the
common stock purchased under the MBL agreement, MBL must give its written
consent with respect to the payment of any dividend, the repurchase of any of
the Company's equity securities, the liquidation or dissolution of the Company
or the amendment of any provision of the Company's Articles of Incorporation or
Bylaws which would adversely affect the rights of MBL under the stock purchase
transaction documents. MBL was granted standard anti-dilution rights with
respect to stock issuances not registered under the Securities Act. MBL also
received standard piggyback registration rights along with certain demand
registration rights.



6. STOCK-BASED COMPENSATION


The Company accounts for its stock plans in accordance with the provisions of
Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to
Employees, SFAS No.148, Accounting for Stock-Based Compensation-Transition and
Disclosure, and related interpretations. As such, compensation expense is
recorded on the date of grant only if the current market price of the underlying
stock exceeds the exercise price. SFAS No. 123, Accounting for Stock-Based
Compensation, permits entities to recognize as expense over the vesting period
the fair value of all stock-based awards on the date of grant. Alternatively,
SFAS No. 123 also allows entities to continue to apply the provisions of APB
Opinion No. 25 and provide pro forma net loss disclosures for employee stock
option grants as if the fair-value-based method defined in SFAS No. 123 had been
applied. The Company has elected to continue to apply the provisions of APB
Opinion No. 25 and provide the pro forma disclosures required by SFAS No. 123.

Had the Company determined compensation cost based on the fair value at the date
of grant for its stock options under SFAS No. 123, the Company's net income
(loss) would have been increased to the pro forma amounts indicated as follows:

                                              Three     Three
                                              Months    Months
                                               Ended    Ended
                                             -------------------
                                            September September
                                                30,       30,
                                             -------------------
                                               2004      2003
                                              -------------------
                                              -------------------

  Net loss as reported                    $ (190,199)   (65,380)
  Deduct    total     stock-based
    employee         compensation
    expense    determined   under
    fair-value   method  for  all
    awards, net of tax                      (10,679)     (15,107)
  Pro forma net loss                       (200,878)     (80,487)
  Net loss per share, basic and
    diluted as reported                       (0.04)       (0.02)
  Net loss per share, basic and
    diluted pro forma                         (0.04)       (0.02)

    Fair value was determined using the Black Scholes option - pricing model.
    There were no stock options granted during the three months ended September
    30, 2004 or September 30, 2003.

7. NOTES PAYABLE

As described in Note 1, Genesis advanced $500,000 to the Company under the
Bridge Note. Interest will not accrue on the principal balance of the Bridge
Note unless and until the merger closing does not occur, in which case the
interest will accrue at the prime rate at the time of such termination and from
said date of termination. Upon a merger termination, the unpaid principal plus
accrued interest thereon is payable in four fully amortized semi-annual
payments. Depending upon the reason for a merger termination, the lender
(Genesis) may elect to convert the unpaid principal balance of the Note plus
accrued but unpaid interest thereon (if any) into shares of common stock of
Corgenix, at a conversion price of $.40 per share if the merger termination is
due to the unrightful refusal to close by Corgenix, or at a conversion price of
$.568 per share if the merger termination is for any other reason. The market
value of the Company's stock was in excess of the potential conversion price at
the date the note was executed, resulting in a beneficial conversion feature of
approximately $660,000. As required by Emerging Issues Task Force Bulletin 98-5,
"Accounting for Convertible Securities with Beneficial Conversion Features of
Contingently Adjustable Conversion Ratios" and 00-27, "Application of Issue 98-5
to Certain Convertible Instruments", the entire proceeds of the Bridge Note were
credited to additional paid-in capital. The Bridge Note was recorded net of a
$500,000 discount, which is being accreted to interest expense over the
potential term of the Bridge Note.
<page>

                                     Item 2.
      CORGENIX MEDICAL CORPORATIONManagement's Discussion and Analysis Of
                  Financial Condition and Results of Operations

The following discussion should be read in conjunction with the consolidated
financial statements and accompanying notes included elsewhere herein.

        General

      Since the Company's inception, we have been primarily involved in the
research, development, manufacturing and marketing/distribution of diagnostic
tests for sale to clinical laboratories. We currently market 73 products
covering autoimmune disorders, vascular diseases, infectious diseases and liver
disease. Our products are sold in the United States, the UK and other countries
through our marketing and sales organization that includes contract sales
representatives, internationally through an extensive distributor network, and
to several significant OEM partners.

      We manufacture products for inventory based upon expected sales demand,
shipping products to customers, usually within 24 hours of receipt of orders if
in stock. Accordingly, we do not operate with a customer order backlog.

      Except for the fiscal year ending June 30, 1997, we have experienced
revenue growth since our inception, primarily from sales of products and
contract revenues from strategic partners. Contract revenues consist of service
fees from research and development agreements with strategic partners.

      Beginning in fiscal year 1996, we began adding third-party OEM licensed
products to our diagnostic product line. Currently we sell 128 products licensed
from or manufactured by third party manufacturers. We expect to expand our
relationships with other companies in the future to gain access to additional
products.

      Although we have experienced growth in revenues every year since 1990,
except for 1997, there can be no assurance that, in the future, we will sustain
revenue growth, current revenue levels, or achieve or maintain profitability.
Our results of operations may fluctuate significantly from period-to-period as
the result of several factors, including: (i) whether and when new products are
successfully developed and introduced, (ii) market acceptance of current or new
products, (iii) seasonal customer demand, (iv) whether and when we receive
research and development payments from strategic partners, (v) changes in
reimbursement policies for the products that we sell, (vi) competitive pressures
on average selling prices for the products that we sell, and (vii) changes in
the mix of products that we sell.

      Critical Accounting Policies

      The Company's consolidated financial statements are prepared in accordance
with accounting principles generally accepted in the United States ("GAAP") and
our significant accounting policies are summarized in Note 1 to the accompanying
consolidated financial statements. The preparation of financial statements in
conformity with GAAP requires management to make estimates and assumptions that
affect reported amounts of assets, liabilities, disclosure of contingent assets
and liabilities at the date of the financial statements and reported amounts of
revenues and expenses during the reporting period. Actual results could differ
significantly from those estimates.

      The Company maintains an allowance for doubtful accounts based on its
historical experience and provides for any specific collection issues that are
identified. Such allowances have historically been adequate to provide for our
doubtful accounts but involve a significant degree of management judgment and
estimation. Worse than expected future economic conditions, unknown customer
credit problems and other factors may require additional allowances for doubtful
accounts to be provided for in future periods. Equipment and software are
recorded at cost. Equipment under capital leases is recorded initially at the
present value of the minimum lease payments. Depreciation and amortization is
calculated primarily using the straight-line method over the estimated useful
lives of the respective assets which range from 3 to 7 years. The internal and
external costs of developing and enhancing software costs related to website
development, other than initial design and other costs incurred during the
preliminary project stage, are capitalized until the software has been
completed. Such capitalized amounts began to be amortized commencing when the
website was placed in service on a straight-line basis over a three-year period.
When assets are sold, retired or otherwise disposed of, the cost and related
accumulated depreciation are eliminated from the accounts and a gain or loss is
recognized. Repair and maintenance costs are expensed as incurred. We evaluate
the realizability of our long-lived assets, including property and equipment,
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Revenue from sale of products is recognized
upon shipment of products. Revenue from research and development contracts
represents amounts earned pursuant to agreements to perform research and
development activities for third parties and is recognized as earned under the
respective agreement. Because research and development services are provided
evenly over the contract period, revenue is recognized ratably over the contract
period. Research and development agreements in effect in 2004 and 2003 provided
for fees to the Company based on time and materials in exchange for performing
specified research and development functions. Research and development and
advertising costs are expensed when incurred. Inventories are recorded at the
lower of cost or market, using the first-in, first-out method.

Results of Operations


      Three Months Ended September 30, 2004 compared to 2003

      Net sales. Net sales for the quarter ended September 30, 2004 were
approximately $1,303,000, an 8.4% increase from approximately $1,202,000 for the
quarter ended September 30, 2003. Domestic sales increased 4.7% while sales to
international distributors increased 20.8% from year to year. With respect to
the Company's major product lines, Phospholipids kit sales increased less than
1% for the fiscal quarter, Coagulation kit sales increased 61.3 %, HA kit sales
decreased 28.2%, and Autoimmune kit sales increased 38.1%. Additionally, OEM
sales decreased less than 1%. Sales of products manufactured for us by other
companies while still relatively small, are expected to continue to increase
during fiscal 2005.

      Cost of sales. Cost of sales, as a percentage of sales, increased to 42.5%
in the quarter ended September 30, 2004 from 39.2% in 2003 primarily due to
higher raw material costs associated with the new manufacturing format of the
Company's main product line, the purchase of certain raw materials which were
formerly manufactured in-house and an increase in scrap costs during the
quarter.

      Selling and marketing. Selling and marketing expenses increased 19.8% to
approximately $376,000 in the quarter ended September 30, 2004 from
approximately $314,000 in 2003. The majority of this increase involved increases
in advertising, commissions and other promotional-related expenses.

      Research and development. Research and development expenses decreased
16.5% to approximately $157,000 in the quarter ended September 30, 2004 from
approximately $188,000 for the quarter ended September 30, 2003. The majority of
this decrease involved reductions in labor-related costs resulting from recently
ended development projects and head-count reductions.

      General and administrative. General and administrative expenses increased
approximately $29,000 or 11.1% to approximately $299,000 in the quarter ended
September 30, 2004 from approximately $270,000 for the quarter ended September
30, 2003, primarily due to increases in outside services, merger-related costs
plus legal expenses.

      Interest expense. Interest expense increased 418.9% to approximately
$104,000 in the quarter ended September 30, 2004 from approximately $25,000 for
the quarter ended September 30, 2003 due primarily to the accretion of discount
on the Bridge Note payable to Genesis plus an increase in interest-bearing debt
partially offset by lower interest rates.
      .
      Liquidity and Capital Resources

      Cash provided by operating activities was $20,858 for the quarter ended
September 30, 2004 compared to cash used in operating activities of $156,577
during the prior year's comparable quarter. This change compared to the year
earlier quarter resulted primarily from a decrease in accounts receivable and an
increase in accounts payable partially offset by an increase in inventories. The
Company believes that uncollectible accounts receivable will not have a
significant effect on future liquidity, as a significant portion of its accounts
receivable are due from financially sound enterprises.

      Net cash used in investing activities, the purchase of equipment, was
$6,528 in the quarter ended September 30, 2004 compared to $3,695 for the year
earlier quarter. The increase was mainly attributable to increased spending on
computers.

      Net cash used in financing activities amounted to $56,388 during the
quarter ended September 30, 2004 compared to cash provided by financing
activities of $24,988 for the year earlier quarter. This change compared to the
year earlier quarter was primarily due to a substantial decrease in the proceeds
from notes payable as a result of the Company's reduced borrowing capacity
pursuant to restrictions imposed by its existing bank loan agreements.

      Historically, we have financed our operations primarily through long-term
debt and by sales of common and preferred stock. No common or preferred stock
was sold in the quarters ended September 30, 2004 or 2003.

      We have also financed operations through sales of diagnostic products and
agreements with strategic partners. Accounts receivable decreased 12.7% to
$728,280 at September 30, 2004 from $834,153 at September 30, 2003 primarily as
a result the accelerated collection of certain accounts.

      Our future capital requirements will depend on a number of factors,
including the proposed merger with Genesis and the possible completion of the
related Takeout Financing for Genesis, the possible redemption of common stock,
our profitability or lack thereof, the rate at which we grow our business and
our investment in proprietary research activities, the ability of our current
and future strategic partners to fund outside research and development
activities, our success in increasing sales of both existing and new products
and collaborations, expenses associated with unforeseen litigation, regulatory
changes, competition, technological developments, general economic conditions
and potential future merger and acquisition activity. Our principal sources of
liquidity have been , cash raised from the private sale of redeemable common and
common stock, the Bridge Note, and long- term debt financing. If completed, the
Takeout Financing would provide approximately $6,000,000 to occur concurrently
with the consummation of the merger with Genesis, now estimated to be on or
about February 28, 2005. If, for any reason the Takeout Financing and the
planned merger with Genesis do not occur or if we are required to repurchase our
redeemable common stock, we will need to implement new expense reductions and
seek new debt agreements and/or sell additional equity securities in fiscal year
2005 to generate additional operating capital, to develop the markets and obtain
the regulatory approvals for our products in the United States, and to pursue
all of our strategic objectives. We believe that our current availability of
cash, working capital, future proceeds from the issuance of common stock and
debt financing and expected cash flows from operations resulting from, if
necessary, further expense reductions, will be adequate to meet our ongoing
needs for at least the next twelve months. At September 30, 2004, cash on hand
amounted to $426,954 compared to $468,954 at June 30, 2003.

<page>

                                       Item 3.

                               Controls and Procedures

      Evaluation of disclosure controls and procedures. The Company, under the
supervision and with the participation of the Company's management, including
its Chief Executive Officer and Chief Financial Officer, carried out an
evaluation of the effectiveness of the design and operation of the Company's
disclosure controls and procedures (as defined in Rules 240.13a-14(c) and
15d-14(c) under the Securities Exchange Act of 1934 (the "Exchange Act") as of a
date within ninety days before the filing date of this quarterly report (the
"Evaluation Date"). Based upon this evaluation, the Chief Executive Officer and
Chief Financial Officer concluded that, as of the Evaluation Date, the Company's
disclosure controls and procedures were effective for the purposes of recording,
processing, summarizing and timely reporting information required to be
disclosed by the Company in the reports that it files under the Securities
Exchange Act of 1934 and that such information is accumulated and communicated
to the Company's management in order to allow timely decisions regarding
required disclosure.

      Changes in internal controls. There have been no significant changes in
the Company's internal controls or in other factors that could significantly
affect the Company's disclosure controls and procedures subsequent to the
Evaluation Date, nor were there any significant deficiencies or material
weaknesses in the Company's internal controls.

      Forward-Looking Statements and Risk Factors

      This 10-QSB includes statements that are not purely historical and are
"forward-looking statements" within the meaning of Section 21E of the Securities
Act of 1934, as amended, including statements regarding our expectations,
beliefs, intentions or strategies regarding the future. All statements other
than historical fact contained in this 10-QSB, including, without limitation,
statements regarding future capital requirements , acquisition strategies,
strategic partnership expectations, technological developments, the development,
the availability of necessary components, research and development programs and
distribution plans, are forward-looking statements. All forward-looking
statements included in this 10-QSB are based on information available to us on
the date hereof, and we assume no obligation to update such forward-looking
statements. Although we believe that the assumptions and expectations reflected
in such forward-looking statements are reasonable, we can give no assurance that
such expectations will prove to have been correct or that we will take any
actions that may presently be planned.

      An investment in Corgenix entails certain risks, and factors that could
cause actual results to differ materially from those expected include the
following:


      Although Corgenix and Genesis expect that the merger will be consummated,
      there can be no assurance that this will occur nor may the anticipated
      benefits of the merger occur.

      The parties are proceeding to effectuate the merger, but there is no
assurance that such a transaction will be consummated. The merger is subject to,
among other conditions, Genesis obtaining additional financing in the amount of
at least $6,000,000. There can be no assurance that such financing can be
obtained. In addition, the merger of Corgenix and Genesis may not be completed
for any variety of reasons, including failure to obtain necessary stockholder
approvals, breach of the parties' representations and warranties and failure to
satisfy other conditions to closing.

      Even if the merger were consummated, the integration of the companies will
be a complex, time consuming and expensive process that may result in disruption
of the business of the combined company. Following the merger, the combined
company must operate as a combined organization utilizing common information and
operating procedures, financial controls, and human resources practices.
Corgenix and Genesis may not accomplish this integration smoothly or
successfully. The diversion of the attention of management from its current
operations to the integration effort and any difficulties encountered in
combining operations could prevent the combined entity from realizing the full
benefits anticipated to result from the merger and adversely affect other
corporate activities.

      In the event of a breach of the merger agreement, the breaching party may
be liable to the other party for up to $1,500,000 of liquidated damages
penalties. There can be no assurance that if a breach occurs, that the breaching
party would be able to meet its liquidated damages obligations.

      Merger-related charges will be incurred.

       Corgenix estimates that, as a result of the merger, the company will
incur certain merger-related expenses of approximately $150,000 consisting of
legal, accounting fees, financial printing and other related charges. The
foregoing amounts are preliminary estimates and the actual amounts may be higher
or lower. In addition, a large portion of the estimated merger-related expenses
are, per agreement with Genesis, to be shared equally with Genesis and thus,
approximately half of said expenses would be reimbursed by Genesis if the merger
is not consummated.

      We continue to incur losses and are likely to require additional
financing.

      We have incurred operating losses and negative cash flow from operations
for most of our history. Losses incurred since our inception have aggregated
$5,065,605 and there can be no assurance that we will be able to generate
positive cash flows to fund our operations in the future or to pursue our
strategic objectives. Assuming no greater than anticipated uses of cash related
to the tentative merger with Genesis or other significant changes, we believe
that we will have sufficient cash to satisfy our needs for at least the next
twelve months. If we are not able to operate profitably and generate positive
cash flows, or complete the merger related Takeout Financing mentioned elsewhere
in this report, we will undoubtedly need to raise additional capital to fund our
operations. If we do in fact need additional financing to meet our requirements,
there can be no assurance that we will be able to obtain such financing on terms
satisfactory to us, if at all. Alternatively, any additional equity financing
may be dilutive to existing stockholders, and debt financing, if available, may
include restrictive covenants. If adequate funds are not available, we might be
required to limit our research and development activities or our selling,
marketing and administrative activities any of which could have a material
adverse effect on the future of the business.

      We depend upon collaborative relationships and third parties for product
      development and commercialization.

      We have historically entered into research and development agreements with
collaborative partners, from which we derived revenues in past years. Pursuant
to these agreements, our collaborative partners have specific responsibilities
for the costs of development, promotion, regulatory approval and/or sale of our
products. We will continue to rely on future collaborative partners for the
development of products and technologies. There can be no assurance that we will
be able to negotiate such collaborative arrangements on acceptable terms, if at
all, or that current or future collaborative arrangements will be successful. To
the extent that we are not able to establish such arrangements, we could be
forced to undertake such activities at our own expense. The amount and timing of
resources that any of these partners devotes to these activities will generally
be based on progress by us in our product development efforts. Collaborative
arrangements may be terminated by the partner upon prior notice without cause
and there can be no assurance that any of these partners will perform its
contractual obligations or that it will not terminate its agreement. With
respect to any products manufactured by third parties, there can be no assurance
that any third-party manufacturer will perform acceptably or that failures by
third parties will not delay clinical trials or the submission of products for
regulatory approval or impair our ability to deliver products on a timely basis.

      There can be no assurance of successful or timely development of
additional products.

      Our business strategy includes the development of additional diagnostic
products for the diagnostic business. Our success in developing new products
will depend on our ability to achieve scientific and technological advances and
to translate these advances into commercially competitive products on a timely
basis. Development of new products requires significant research, development
and testing efforts. We have limited resources to devote to the development of
products and, consequently, a delay in the development of one product or the use
of resources for product development efforts that prove unsuccessful may delay
or jeopardize the development of other products. Any delay in the development,
introduction and marketing of future products could result in such products
being marketed at a time when their cost and performance characteristics would
not enable them to compete effectively in their respective markets. If we are
unable, for technological or other reasons, to complete the development and
introduction of any new product or if any new product is not approved or cleared
for marketing or does not achieve a significant level of market acceptance, our
ability to remain competitive in our product niches would be impaired.

      Competition in the human medical diagnostics industry is, and is expected
      to remain, significant.

      Our competitors range from development stage diagnostics companies to
major domestic and international pharmaceutical companies. Many of these
companies have financial, technical, marketing, sales, manufacturing,
distribution and other resources significantly greater than ours. In addition,
many of these companies have name recognition, established positions in the
market and long standing relationships with customers and distributors.
Moreover, the diagnostics industry has recently experienced a period of
consolidation, during which many of the large domestic and international
pharmaceutical companies have been acquiring mid-sized diagnostics companies,
further increasing the concentration of resources. There can be no assurance
that technologies will not be introduced that could be directly competitive with
or superior to our technologies.

      Our products and activities are subject to regulation by various
      governments and government agencies.

      The testing, manufacture and sale of our products is subject to regulation
by numerous governmental authorities, principally the United States Food and
Drug Administration and certain foreign regulatory agencies. Pursuant to the
Federal Food, Drug, and Cosmetic Act, and the regulations promulgated there
under, the FDA regulates the preclinical and clinical testing, manufacture,
labeling, distribution and promotion of medical devices. We are not able to
commence marketing or commercial sales in the United States of new products
under development until we receive clearance from the FDA. The testing for,
preparation of and subsequent FDA regulatory review of required filings can be a
lengthy, expensive and uncertain process. Noncompliance with applicable
requirements can result in, among other consequences, fines, injunctions, civil
penalties, recall or seizure of products, repair, replacement or refund of the
cost of products, total or partial suspension of production, failure of the
government to grant pre-market clearance or pre-market approval for devices,
withdrawal of marketing clearances or approvals, and criminal prosecution.

      There can be no assurance that we will be able to obtain necessary
regulatory approvals or clearances for our products on a timely basis, if at
all, and delays in receipt of or failure to receive such approvals or
clearances, the loss of previously received approvals or clearances, limitations
on intended use imposed as a condition of such approvals or clearances or
failure to comply with existing or future regulatory requirements could
negatively impact our sales and thus have a material adverse effect on our
business.

      As a manufacturer of medical devices for marketing in the United States,
we are required to adhere to applicable regulations setting forth detailed good
manufacturing practice requirements, which include testing, control and
documentation requirements. We must also comply with Medical Device Report (MDR)
requirements, which require that a manufacturer reports to the FDA any incident
in which its product may have caused or contributed to a death or serious
injury, or in which its product malfunctioned and, if the malfunction were to
recur, it would be likely to cause or contribute to a death or serious injury.
We are also subject to routine inspection by the FDA for compliance with Quality
System Regulations (QSR) requirements, MDR requirements and other applicable
regulations. Labeling and promotional activities are subject to scrutiny by the
FDA and, in certain circumstances, by the Federal Trade Commission. We may incur
significant costs to comply with laws and regulations in the future, which would
decrease our net income or increase our net loss and thus have a potentially
material adverse effect upon our business, financial conditions and results of
operations.

      Distribution of diagnostic products outside the United States is subject
to extensive foreign government regulation. These regulations, including the
requirements for approvals or clearance to market, the time required for
regulatory review and the sanctions imposed for violations, vary from country to
country. We may be required to incur significant costs in obtaining or
maintaining foreign regulatory approvals. In addition, the export of certain of
our products that have not yet been cleared for domestic commercial distribution
may be subject to FDA export restrictions. Failure to obtain necessary
regulatory approval or the failure to comply with regulatory requirements could
reduce our product sales and thus have a potentially material adverse effect on
our business, financial condition and results of operations.
<page>
      We depend upon distribution partners for sales of diagnostic products in
      international markets.

      We have entered into distribution agreements with collaborative partners
in which we have granted distribution rights for certain of our products to
these partners within specific international geographic areas. Pursuant to these
agreements, our collaborative partners have certain responsibilities for market
development, promotion, and sales of the products. If any of these partners
fails to perform its contractual obligations or terminates its agreement, this
could have a reduce our sales and cash flow and thus have a potentially material
adverse effect on our business, financial condition and results of operations.

      Third party reimbursement for purchases of our diagnostic products is
      uncertain.

      In the United States, health care providers that purchase diagnostic
products, such as hospitals and physicians, generally rely on third party
payers, principally private health insurance plans, federal Medicare and state
Medicaid, to reimburse all or part of the cost of the purchase. Third party
payers are increasingly scrutinizing and challenging the prices charged for
medical products and services and they can affect the pricing or the relative
attractiveness of the product. Decreases in reimbursement amounts for tests
performed using our diagnostic products, failure by physicians and other users
to obtain reimbursement from third party payers, or changes in government and
private third party payers' policies regarding reimbursement of tests utilizing
diagnostic products, may affect our ability to sell our diagnostic products
profitably. Market acceptance of our products in international markets is also
dependent, in part, upon the availability of reimbursement within prevailing
health care payment systems.

      Our success depends, in part, on our ability to obtain patents and license
      patent rights, to maintain trade secret protection and to operate without
      infringing on the proprietary rights of others.

      There can be no assurance that our issued patent will afford meaningful
protection against a competitor, or that patents issued to us will not be
infringed upon or designed around by others, or that others will not obtain
patents that we would need to license or design around. We could incur
substantial costs in defending the Company or our licensees in litigation
brought by others. The potential for reduced sales and increased legal expenses
would have a negative impact on our cash flow and thus our overall business
could be adversely affected.

      We may not be able to successfully implement our plans to acquire other
      companies or technologies.

      Our growth strategy may include the acquisition of complementary
companies, products or technologies. There is no assurance that we will be able
to identify appropriate companies or technologies to be acquired, to negotiate
satisfactory terms for such an acquisition, or to obtain sufficient capital to
make such acquisitions. Moreover, because of limited cash resources, we will be
unable to acquire any significant companies or technologies for cash and our
ability to effect acquisitions in exchange for our capital stock may depend upon
the market prices for our common stock, which could result in significant
dilution to its existing stockholders. If we do complete one or more
acquisitions, a number of risks arise, such as disruption of our existing
business, short-term negative effects on our reported operating results,
diversion of management's attention, unanticipated problems or legal
liabilities, and difficulties in the integration of potentially dissimilar
operations. Any of these factors could materially harm Corgenix's business or
its operating results.

      We depend on suppliers for our products' components.

      The components of our products include chemical and packaging supplies
that are generally available from several suppliers, except certain antibodies,
which we purchases from single suppliers. We mitigate the risk of a loss of
supply by maintaining a sufficient supply of such antibodies to ensure an
uninterrupted supply for at least three months. We have also qualified second
vendors for all critical raw materials and believe that we can substitute a new
supplier with respect to any of these components in a timely manner. If, for
some reason, we lose our main supplier for a given material, there can be no
assurances that we will be able to substitute a new supplier in a timely manner
and failure to do so could impair the manufacturing of certain of our products
and thus have a material adverse effect on our business, financial condition and
results of operations.

      We have only limited manufacturing experience with certain products.

      Although we have manufactured over twelve million diagnostic tests based
on our proprietary applications of ELISA (enzyme linked immuno-absorbent assay)
technology, certain of our diagnostic products in consideration for future
development, incorporate technologies with which we have little manufacturing
experience. Assuming successful development and receipt of required regulatory
approvals, significant work may be required to scale up production for each new
product prior to such product's commercialization. There can be no assurance
that such work can be completed in a timely manner and that such new products
can be manufactured cost-effectively, to regulatory standards or in sufficient
volume.

      Due to the specialized nature of our business, our success will be highly
      dependent upon our ability to attract and retain qualified scientific and
      executive personnel.

      We believe our success will depend to a significant extent on the efforts
and abilities of Dr. Luis R. Lopez and Douglass T. Simpson, who would be
difficult to replace. There can be no assurance that we will be successful in
attracting and retaining such skilled personnel, who are generally in high
demand by other companies. The loss of, inability to attract, or poor
performance by key scientific and executive personnel may have a material
adverse effect on our business, financial condition and results of operations.

      The testing, manufacturing and marketing of medical diagnostic devices
      entails an inherent risk of product liability claims.

      To date, we have experienced no product liability claims, but any such
claims arising in the future could have a material adverse effect on our
business, financial condition and results of operations. Potential product
liability claims may exceed the amount of our insurance coverage or may be
excluded from coverage under the terms of our policy or limited by other claims
under our umbrella insurance policy. Additionally, there can be no assurance
that our existing insurance can be renewed by us at a cost and level of coverage
comparable to that presently in effect, if at all. In the event that we are held
liable for a claim against which we are not insured or for damages exceeding the
limits of our insurance coverage, such claim could have a material adverse
effect on our cash flow and thus potentially a materially adverse effect on our
business, financial condition and results of operations.

      There has, to date, been no active public market for our common stock, and
      there can be no assurance that an active public market will develop or be
      sustained.

      Although our common stock has been traded on the OTC Bulletin Board since
February 1998, the trading has been sporadic with insignificant volume.

      Moreover, the over-the-counter markets for securities of very small
companies historically have experienced extreme price and volume fluctuations.
These broad market fluctuations and other factors, such as new product
developments, trends in our industry, the investment markets, economic
conditions generally, and quarterly variation in our results of operations, may
adversely affect the market price of our common stock. In addition, our common
stock is subject to rules adopted by the Securities and Exchange Commission
regulating broker-dealer practices in connection with transactions in "penny
stocks." Such rules require the delivery prior to any penny stock transaction of
a disclosure schedule explaining the penny stock market and all associated risks
and impose various sales practice requirements on broker-dealers who sell penny
stocks to persons other than established customers and accredited investors,
which are generally defined as institutions or an investor with a net worth in
excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together
with the spouse. For these types of transactions the broker-dealer must make a
special suitability determination for the purchaser and have received the
purchaser's written consent to the transaction prior to sale. The additional
burdens imposed upon broker-dealers by such requirements may discourage
broker-dealers from effecting transactions in securities subject to the penny
stock rules.

      There are risks associated with fluctuating exchange rates.

  Our financial statements are presented in US dollars. At the end of each
fiscal quarter and the fiscal year, we convert the financial statements of
Corgenix UK, which operates in pounds sterling, into US dollars, and consolidate
them with results from Corgenix, Inc. We may, from time to time, also need to
exchange currency from income generated by Corgenix UK. Foreign exchange rates
are volatile and can change in an unknown and unpredictable fashion. Should the
foreign exchange rates change to levels different than anticipated by us, our
business, financial condition and results of operations may be adversely
affected.
<page>
                          CORGENIX MEDICAL CORPORATION


                                     PART II


                                Other Information


Item 1.    Legal Proceedings


       None.


Item 2.    Changes in Securities and Use of Proceeds


      None

Item 3.    Defaults Upon Senior Securities


      None


Item 4.    Submission of Matters to a Vote of Security Holders


      None


Item 5.    Other Information


      None

Item 6.  Exhibits and Reports on Form 8-K.

a. Index to and Description of Exhibits.


Exhibit
Number   Description of Exhibit

2.1      Agreement and Plan of Merger dated as of March 12, 2004 by
         and among Genesis Bioventures, Inc., GBI Acquisition
         Corporation and Corgenix Medical Corporation.
2.2      Amended and Restated Agreement and Plan of Merger as of
         May 21, 2004 by and among Genesis Bioventures, Inc., GBI
         Acquisition Corporation and Corgenix Medical Corporation.
2.3*     Amendment No. 1 to Amended and Restated Agreement and Plan
         of Merger as of October 15, 2004 by and among Genesis
         Bioventures, Inc., GBI Acquisition Corporation and
         Corgenix Medical Corporation.
3.1      Articles of Incorporation, as amended (filed with the Company's
         Registration Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference).
3.2      Bylaws (filed with the Company's Registration Statement on Form 10-SB
         filed June 29, 1998, and incorporated herein by reference).

10.4     License Agreement dated June 30, 2001 between Chugai
         Diagnostic Science Co., Ltd. and Corgenix Medical
         Corporation (filed with the Company's Form 10-KSB, and
         incorporated herein by reference).

10.5     Office Lease dated May 5, 2001 between Crossroads West
         LLC/Decook Metrotech LLC and Corgenix, Inc. (filed with
         the Company's Form-10KSB, and incorporated herein by
         reference).
10.6     Guarantee dated November 1, 1997 between William George Fleming,
         Douglass Simpson and Geoffrey Vernon Callen (filed with the Company's
         Registration Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference).
10.7     Employment Agreement dated April 1, 2001 between Luis R. Lopez and the
         Company filed with the Company's Form 10-KSB, and incorporated herein
         by reference.

10.8     Employment Agreement dated April 1, 2001 between Douglass T. Simpson
         and the Company filed with the Company's Form 10-KSB, and incorporated
         herein by reference.
10.9     Employment Agreement dated April 1, 2001 between Ann L. Steinbarger and
         the Company filed with the Company's Form 10-KSB, and incorporated
         herein by reference.
10.10    Employment Agreement dated April 1, 2001 between Taryn G. Reynolds and
         the Company filed with the Company's Form 10-KSB, and incorporated
         herein by reference.
10.11    Employment Agreement dated April 1, 2001 between Catherine (O'Sullivan)
         Fink and the Company filed with the Company's Form 10-KSB, and
         incorporated herein by reference.
10.14    Note dated January 6, 1997 between REAADS Medical Products, Inc. and
         Eagle Bank (filed with the Company's Registration Statement on Form
         10-SB filed June 29, 1998, and incorporated herein by reference).
10.15    Form of Indemnification Agreement between the Company and its directors
         and officers (filed with the Company's Registration Statement on Form
         10-SB/A-1 filed September 24, 1998 and incorporated herein by
         reference).
10.16    Warrant agreement dated June 1, 2000 between the Company and Taryn G.
         Reynolds filed with the Company's Form 10-KSB, and incorporated herein
         by reference.
10.17    Employment Agreement dated March 1, 2001 between William H. Critchfield
         and the Company (filed with the Company's filing on Form 10-QSB for the
         fiscal quarter ended March 31, 2001).
10.19    Consulting Agreement dated September 29, 2002 between Eiji Matsuura,
         Ph.D and the Company filed with the Company's Form 10-QSB, and
         incorporated herein by reference.
10.20    License Agreement dated September 29, 2002 between Eiji Matsuura, Ph.D
         and the Company filed with the Company's Form 10-QSB, and incorporated
         herein by reference.
10.23    Amended and Restated 1999 Incentive Stock Plan.
10.24    Amended and Restated Employee Stock Purchase Plan.
10.28    Warrant Agreement dated October 11, 2001 between Phillips
         V. Bradford and the Company, filed with the Company's Form 10-QSB, and
         incorporated herein by reference.
10.29    Warrant Agreement dated October 11, 2001 between Charles F. Ferris and
         the Company filed with the Company's Form 10-QSB, and incorporated
         herein by reference.
10.30    Underlease Agreement dated October 3, 2001 between G.V. Callen, A.G.
         Pirmohamed and Corgenix UK, Ltd. filed with the Company's Form 10-QSB,
         and incorporated herein by reference.
10.31    Distribution and OEM Agreement dated March 14, 2002 between RhiGene,
         Inc. and the Company filed with the Company's Form 10-QSB, and
         incorporated herein by reference.
21.1     Amended Subsidiaries of the Registrant (filed as Exhibit 21.1 to the
         Company's Registration Statement on Form 10-SB filed June 29, 1998).
31.1*    Certification pursuant to section 302 of the
         Sarbanes-Oxley Act of 2002.
31.2*    Certification pursuant to section 302 of the
         Sarbanes-Oxley Act of 2002
31.3*    Certification pursuant to section 302 of the
         Sarbanes-Oxley Act of 2002
32.1*    Certification by Chief Executive Officer pursuant to 18 U.S.C. Section
         1350, or adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
         2002.
32.2*    Certification by Principal Financial Officer pursuant to 18 U.S.C.
         Section 1350, or adopted pursuant to Section 906 of the Sarbanes-Oxley
         Act of 2002.
* Filed Herewith
---------------------------------------
      (b) Reports on Form 8-K.

1.           Form 8-K filed September 23, 2004 Entry Into Material Definitive
             Agreement.

           2. Form 8-K filed October 21, 2004 Entry into Material Definitive
Agreement.
<page>
                                                                    Exhibit 31.1
                                 CERTIFICATIONS

I, Luis R. Lopez, Chief Executive Officer, certify that:

   1. I have reviewed this quarterly report on Form 10-QSB of Corgenix Medical
   Corporation.

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.         Based on my knowledge, the financial statements, and other financial
           information included in this report, fairly present in all material
           respects the financial condition, results of operations and cash
           flows of the registrant as of, and for, the periods presented in this
           quarterly report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           for the small business issuer and have:

a.         Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this quarterly report is being prepared;
b.         Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
c.         Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of an annual
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed , based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

a.         All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
b.         Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.

Date:  November 12, 2004


/S/Luis R. Lopez
Chief Executive Officer
<page>
                                                                    Exhibit 31.2
                                 CERTIFICATIONS



I, William H. Critchfield, Chief Financial Officer, certify that:

   1. I have reviewed this quarterly report on Form 10-QSB of Corgenix Medical
      Corporation.

   2. Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.    Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the registrant as of, and for, the periods presented in this quarterly
      report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           for the small business issuer and have:

a.         Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this quarterly report is being prepared;
b.         Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
c.         Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of an annual
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed , based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

a.         All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
b.         Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.

Date:  November 12, 2004


/S/William H. Critchfield
Chief Financial Officer

<page>
                                                                    Exhibit 31.3

                                 CERTIFICATIONS



I, Douglass T. Simpson, President, certify that:

   1. I have reviewed this quarterly report on Form 10-QSB of Corgenix Medical
      Corporation.

   2. Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.    Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the registrant as of, and for, the periods presented in this quarterly
      report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           for the small business issuer and have:

a.         Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this quarterly report is being prepared;
b.         Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
c.         Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of an annual
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed, based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

a.         All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
b.         Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.

Date:  November 12, 2004


/S/Douglass T. Simpson
President

<page>
                                                                    Exhibit 32.1


                                  CERTIFICATION
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
        SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
                               UNITED STATES CODE

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b)of section 1350, chapter 63 of Title 18, United States Code), I Douglass T.
Simpson, President of Corgenix Medical Corporation, a Nevada corporation (the
"Company"), does hereby certify with respect to the Quarterly Report of the
Company on Form 10-QSB for the quarter ended September 30, 2004 as filed with
the Securities an Exchange Commission (the "10-QSB Report") that:

(i)              the 10-QSB Report fully complies with the requirements of
                 section 13(a) or 15(d) of the Securities Exchange Act of 1934;
                 and

               (ii) the information contained in the 10-QSB Report fairly
                 presents, in all material respects, the financial condition and
                 results of operations of the Company.


           Dated:    November 12, 2004





           This Certification is made solely for purposes of 18 U.S.C. Section
           1350, subject to the knowledge standard contained therein, and not
           for any other purpose.

           A signed original of this written statement required by Section 906
           of the Sarbanes-Oxley Act has been provided to the Company and will
           be retained by the Company and furnished to the Securities and
           Exchange Commission or its staff request. This written statement
           shall not be deemed to be "filed" as part of the quarterly report on
           Form 10-QSB that it accompanies.


/S/ Douglass T. Simpson
 President
<page>
                                                                    Exhibit 32.2


                                  CERTIFICATION
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
        SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
                               UNITED STATES CODE

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b)of section 1350, chapter 63 of Title 18, United States Code), I William H.
Critchfield, Chief Financial Officer of Corgenix Medical Corporation, a Nevada
corporation (the "Company"), does hereby certify with respect to the Quarterly
Report of the Company on Form 10-QSB for the quarter ended September 30, 2004 as
filed with the Securities an Exchange Commission (the "10-QSB Report") that:

(j)              the 10-QSB Report fully complies with the requirements of
                 section 13(a) or 15(d) of the Securities Exchange Act of 1934;
                 and

               (ii) the information contained in the 10-QSB Report fairly
                 presents, in all material respects, the financial condition
                and results of operations of the Company.


           Dated:    November 12, 2004





           This Certification is made solely for purposes of 18 U.S.C. Section
           1350, subject to the knowledge standard contained therein, and not
           for any other purpose.

           A signed original of this written statement required by Section 906
           of the Sarbanes-Oxley Act has been provided to the Company and will
           be retained by the Company and furnished to the Securities and
           Exchange Commission or its staff request. This written statement
           shall not be deemed to be "filed" as part of the quarterly reporton
           Form 10-QSB that it accompanies.

/S/ William H. Critchfield
Chief  Financial Officer
<page>

                                   SIGNATURES


      In accordance with the requirements of the Securities Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
                                    CORGENIX MEDICAL CORPORATION
November 12, 2004                  By:/s/ Luis R. Lopez
                                      Luis R. Lopez, M.D.
                                   Chairman and Chief Executive Officer